• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

晚期前列腺癌患者停用甲地孕酮后前列腺特异性抗原显著下降：抗雄激素撤药综合征的扩展

Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.

作者信息

Dawson N A, McLeod D G

机构信息

Hematology-Oncology Services, Walter Reed Army Medical Center, Washington, D.C., USA.

出版信息

J Urol. 1995 Jun;153(6):1946-7.

PMID:7538601
Abstract

We report a dramatic decrease in prostate specific antigen in response to the discontinuation of megestrol acetate in a patient with progressive metastatic prostate cancer. Our case demonstrates that withdrawal responses may occur with steroidal and nonsteroidal antiandrogens.

摘要

我们报告了一例进展性转移性前列腺癌患者停用醋酸甲地孕酮后前列腺特异性抗原显著下降的情况。我们的病例表明，甾体类和非甾体类抗雄激素药物都可能出现撤药反应。

相似文献

1
Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.晚期前列腺癌患者停用甲地孕酮后前列腺特异性抗原显著下降：抗雄激素撤药综合征的扩展
J Urol. 1995 Jun;153(6):1946-7.
2
Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.醋酸氯地孕酮甾体类抗雄激素治疗后前列腺癌患者的抗雄激素撤药综合征
Urology. 1995 Apr;45(4):700-4; discussion 704-5. doi: 10.1016/S0090-4295(99)80070-3.
3
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.初始最大雄激素阻断治疗后复发的晚期前列腺癌的替代性非甾体抗雄激素治疗
J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.
4
Complete response, as determined by prostate-specific antigen level, to chlormadinone acetate withdrawal persisting longer than 2 years in patients with advanced prostate cancer: two case reports.根据前列腺特异性抗原水平确定的完全缓解，在晚期前列腺癌患者中醋酸氯地孕酮撤药后持续超过2年：两例病例报告。
Int J Urol. 2006 Sep;13(9):1259-61. doi: 10.1111/j.1442-2042.2006.01515.x.
5
Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer.
Mayo Clin Proc. 1997 Oct;72(10):932-4. doi: 10.1016/S0025-6196(11)63364-8.
6
Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.停用低剂量醋酸甲地孕酮后前列腺特异性抗原的下降
J Clin Oncol. 1999 Mar;17(3):1087-8.
7
[Antiandrogen withdrawal syndrome].[抗雄激素撤药综合征]
Nihon Rinsho. 1998 Aug;56(8):2135-9.
8
Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.比卡鲁胺撤药现象导致前列腺特异性抗原反应无法检测到。
Tech Urol. 2000 Sep;6(3):221-2.
9
[Evaluation of megestrol acetate as monotherapy in disseminated prostatic carcinoma].[醋酸甲地孕酮作为转移性前列腺癌单一疗法的评估]
Arch Esp Urol. 1998 Mar;51(2):151-3.
10
Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.激素难治性前列腺癌患者停用磷酸雌莫司汀后前列腺特异性抗原急剧下降。
Int J Urol. 2006 Jul;13(7):1019-21. doi: 10.1111/j.1442-2042.2006.01465.x.

引用本文的文献

1
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.全面分析晚期前列腺癌患者循环肿瘤 DNA 中的 AR 改变。
Oncologist. 2020 Apr;25(4):327-333. doi: 10.1634/theoncologist.2019-0115. Epub 2019 Nov 11.
2
Switching and withdrawing hormonal agents for castration-resistant prostate cancer.去势抵抗性前列腺癌的激素药物转换和停药。
Nat Rev Urol. 2015 Jan;12(1):37-47. doi: 10.1038/nrurol.2014.345.
3
Delayed antiandrogen withdrawal syndrome after discontinuation of bicalutamide.
比卡鲁胺停药后迟发性抗雄激素撤药综合征
Clin Genitourin Cancer. 2015 Feb;13(1):e51-3. doi: 10.1016/j.clgc.2014.08.015. Epub 2014 Sep 22.
4
Identification of a new androgen receptor (AR) co-regulator BUD31 and related peptides to suppress wild-type and mutated AR-mediated prostate cancer growth via peptide screening and X-ray structure analysis.通过肽筛选和 X 射线结构分析鉴定一种新的雄激素受体（AR）共调节剂 BUD31 和相关肽，以抑制野生型和突变型 AR 介导的前列腺癌生长。
Mol Oncol. 2014 Dec;8(8):1575-87. doi: 10.1016/j.molonc.2014.06.009. Epub 2014 Jun 24.
5
Novel agents in the management of castration resistant prostate cancer.去势抵抗性前列腺癌治疗中的新型药物
J Carcinog. 2014 Mar 5;13:5. doi: 10.4103/1477-3163.128185. eCollection 2014.
6
Safety of megestrol acetate in palliating anorexia-cachexia syndrome in patients with castration-resistant prostate cancer.甲地孕酮醋酸酯在缓解去势抵抗性前列腺癌患者恶病质-厌食症综合征中的安全性。
J Korean Med Sci. 2013 May;28(5):687-92. doi: 10.3346/jkms.2013.28.5.687. Epub 2013 May 2.
7
[How should hormone therapy for castration-resistant prostate cancer be continued?].[去势抵抗性前列腺癌的激素治疗应如何持续？]
Urologe A. 2012 Jan;51(1):15-9. doi: 10.1007/s00120-011-2738-9.
8
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).去势抵抗性前列腺癌的抗雄激素撤药治疗：一项西南肿瘤协作组试验（SWOG 9426）
Cancer. 2008 Jun;112(11):2393-400. doi: 10.1002/cncr.23473.
9
[Therapy of hormone-refractory prostate cancer].
Urologe A. 2005 Dec;44(12):1481-94; quiz 1495. doi: 10.1007/s00120-005-0980-8.
10
[Treatment options for hormone-refractory prostate cancer].[激素难治性前列腺癌的治疗选择]
Urologe A. 2005 Nov;44(11):1303-4, 1306-14. doi: 10.1007/s00120-005-0928-z.